FAJARDO, Puerto Rico, July 31 /PRNewswire/ -- Warner Chilcott Company,
Inc. announced today that it has filed suit against Watson Laboratories,
Inc. and Watson Pharmaceuticals, Inc. in the United States District Court
for the District of New Jersey alleging infringement of Warner Chilcott's
U.S. patent that protects Loestrin(R) 24 Fe.
The lawsuit is in response to an Abbreviated New Drug Application filed
by Watson with the FDA regarding Watson's intent to market a generic
version of Loestrin(R) 24 Fe prior to the expiration of Warner Chilcott's
U.S. Patent No. 5,552,394.
Warner Chilcott has full confidence in, and will continue to vigorously
defend and enforce, its intellectual property rights protecting Loestrin(R)
Warner Chilcott is a leading specialty pharmaceutical company focused
on developing, manufacturing and marketing and selling branded prescription
products in women's healthcare and dermatology in the United States.
Forward Looking Statements
This press release contains forward-looking statements, including
statements concerning our operations, our economic performance and
financial condition, and our business plans and growth strategy and product
development efforts. These statements constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. The words "may," "might,"
"will," "should," "estimate," "project," "plan," "anticipate," "expect,"
intend," "outlook," "believe" and other similar expressions are intended to
identify forward- looking statements. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
their dates. These forward-looking statements are based on estimates and
assumptions by our management that, although we believe to be reasonable,
are inherently uncertain and subject to a number of risks and
The following represent some, but not necessarily all, of the factors
that could cause actual results to differ from historical results or those
anticipated or predicted by our forward-looking statements: our substantial
indebtedness; competitive factors in the industry in which we operate; our
ability to protect our intellectual property; a delay in qualifying our
manufacturing facility to produce our products or production or regulatory
problems with either third party manufacturers upon whom we may rely for
some of our products or our own manufacturing facility; pricing pressures
from reimbursement policies of private managed care organizations and other
third party payors, government sponsored health systems, the continued
consolidation of the distribution network through which we sell our
products, including wholesale drug distributors and the growth of large
retail drug store chains; the loss of key senior management or scientific
staff; an increase in litigation, including product liability claims and
patent litigation; government regulation affecting the development,
manufacture, marketing and sale of pharmaceutical products, including our
ability and the ability of companies with whom we do business to obtain
necessary regulatory approvals; our ability to successfully complete the
implementation of a company-wide enterprise resource planning system
without disrupting our business; our ability to manage the growth of our
business by successfully identifying, developing, acquiring or licensing
and marketing new products, obtain regulatory approval and customer
acceptance of those products, and continued customer acceptance of our
existing products; and other risks detailed from time-to-time in our
financial statements and other investor communications.
We caution you that the foregoing list of important factors is not
exclusive. In addition, in light of these risks and uncertainties, the
matters referred to in our forward-looking statements may not occur. We
undertake no obligation to publicly update or revise any forward-looking
statement as a result of new information, future events or otherwise,
except as may be required by law.
SOURCE Warner Chilcott Company, Inc.